Literature DB >> 20447873

Fluorodeoxyglucose positron emission tomography of mild cognitive impairment with clinical follow-up at 3 years.

José V Pardo1, Joel T Lee, Michael A Kuskowski, Kristin R Munch, John V Carlis, Sohail A Sheikh, Christa Surerus, Scott M Lewis, J Riley McCarten, Howard Fink, Susan McPherson, Hemant H Shah, Susan Rottunda, Maurice W Dysken.   

Abstract

BACKGROUND: Alzheimer's disease (AD) is the most common dementing illness. Development of effective treatments directed at AD requires an early diagnosis. Mild cognitive impairment (MCI) often heralds AD. Thus, characterizing MCI is fundamental to the early diagnosis of AD.
METHODS: 19 MCI patients referred from a memory loss clinic and 27 healthy subjects, all followed up for 3 years. Metabolism scans (MCI minus controls) were compared voxel-wise after anatomic normalization and were examined both visually and with a computerized classifier.
RESULTS: Agreement between raters as to whether the individual scans were normal or abnormal was high. Agreement between raters of the eventual clinical diagnosis and baseline metabolic pattern was poor. A computerized classifier was unsuccessful at classifying MCI from normal; however, its performance improved when using only prototypic AD-like MCI scans, indicating the classifier worked well when shared patterns existed in the data. Outcomes on follow-up were nine of 19 AD, five of 19 remained MCI, and five of 19 developed dementias other than AD. Both MCI cases of early Lewy body dementia (LBD) showed an AD-like metabolic pattern.
CONCLUSIONS: Visual inspection proved reliable in determining normal from abnormal scans, but it proved unreliable at predicting diagnosis on follow-up. Computerized classification of MCI by using an AD-like metabolic template (such as derived from the averaged MCI images) showed potential to identify patients who will develop AD. However, the metabolic pattern in early LBD did not differ from that in AD. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20447873      PMCID: PMC2918397          DOI: 10.1016/j.jalz.2009.09.005

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  33 in total

1.  Mild cognitive impairment: clinical characterization and outcome.

Authors:  R C Petersen; G E Smith; S C Waring; R J Ivnik; E G Tangalos; E Kokmen
Journal:  Arch Neurol       Date:  1999-03

2.  Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET.

Authors:  Alexander Drzezga; Timo Grimmer; Matthias Riemenschneider; Nicola Lautenschlager; Hartwig Siebner; Panagiotis Alexopoulus; Satoshi Minoshima; Markus Schwaiger; Alexander Kurz
Journal:  J Nucl Med       Date:  2005-10       Impact factor: 10.057

3.  Posterior cingulate cortex in Alzheimer's disease.

Authors:  S Minoshima; N L Foster; D E Kuhl
Journal:  Lancet       Date:  1994-09-24       Impact factor: 79.321

4.  Mortality in amnestic mild cognitive impairment: a prospective community study.

Authors:  A L Hunderfund; R O Roberts; T C Slusser; C L Leibson; Y E Geda; R J Ivnik; E G Tangalos; R C Petersen
Journal:  Neurology       Date:  2006-11-28       Impact factor: 9.910

5.  Neuropathologic substrate of mild cognitive impairment.

Authors:  William R Markesbery; Frederick A Schmitt; Richard J Kryscio; Daron G Davis; Charles D Smith; David R Wekstein
Journal:  Arch Neurol       Date:  2006-01

6.  (18)F-FDG PET database of longitudinally confirmed healthy elderly individuals improves detection of mild cognitive impairment and Alzheimer's disease.

Authors:  Lisa Mosconi; Wai Hon Tsui; Alberto Pupi; Susan De Santi; Alexander Drzezga; Satoshi Minoshima; Mony J de Leon
Journal:  J Nucl Med       Date:  2007-06-15       Impact factor: 10.057

7.  Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias.

Authors:  Lisa Mosconi; Wai H Tsui; Karl Herholz; Alberto Pupi; Alexander Drzezga; Giovanni Lucignani; Eric M Reiman; Vjera Holthoff; Elke Kalbe; Sandro Sorbi; Janine Diehl-Schmid; Robert Perneczky; Francesca Clerici; Richard Caselli; Bettina Beuthien-Baumann; Alexander Kurz; Satoshi Minoshima; Mony J de Leon
Journal:  J Nucl Med       Date:  2008-02-20       Impact factor: 10.057

Review 8.  Mild cognitive dysfunction: an epidemiological perspective with an emphasis on African Americans.

Authors:  Frederick W Unverzagt; Kathleen A Lane; Christopher Callahan; Adesola Ogunniyi; Olusegun Baiyewu; Oye Gureje; Kathleen S Hall; Hugh C Hendrie
Journal:  J Geriatr Psychiatry Neurol       Date:  2007-12       Impact factor: 2.680

9.  Atrophy rates accelerate in amnestic mild cognitive impairment.

Authors:  C R Jack; S D Weigand; M M Shiung; S A Przybelski; P C O'Brien; J L Gunter; D S Knopman; B F Boeve; G E Smith; R C Petersen
Journal:  Neurology       Date:  2007-11-21       Impact factor: 9.910

10.  A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET.

Authors:  S Minoshima; K A Frey; R A Koeppe; N L Foster; D E Kuhl
Journal:  J Nucl Med       Date:  1995-07       Impact factor: 10.057

View more
  6 in total

Review 1.  Clinical utility of FDG-PET for the clinical diagnosis in MCI.

Authors:  Javier Arbizu; Cristina Festari; Daniele Altomare; Zuzana Walker; Femke Bouwman; Jasmine Rivolta; Stefania Orini; Henryk Barthel; Federica Agosta; Alexander Drzezga; Peter Nestor; Marina Boccardi; Giovanni Battista Frisoni; Flavio Nobili
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-04-27       Impact factor: 9.236

Review 2.  A Cochrane review on brain [¹⁸F]FDG PET in dementia: limitations and future perspectives.

Authors:  Silvia Morbelli; Valentina Garibotto; Elsmarieke Van De Giessen; Javier Arbizu; Gaël Chételat; Alexander Drezgza; Swen Hesse; Adriaan A Lammertsma; Ian Law; Sabina Pappata'; Pierre Payoux; Marco Pagani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-09       Impact factor: 9.236

Review 3.  ¹⁸F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

Authors:  Nadja Smailagic; Marco Vacante; Chris Hyde; Steven Martin; Obioha Ukoumunne; Christos Sachpekidis
Journal:  Cochrane Database Syst Rev       Date:  2015-01-28

4.  A preliminary study of resting brain metabolism in treatment-resistant depression before and after treatment with olanzapine-fluoxetine combination.

Authors:  José V Pardo; Sohail A Sheikh; Graeme Schwindt; Joel T Lee; David E Adson; Barry Rittberg; Faruk S Abuzzahab
Journal:  PLoS One       Date:  2020-01-13       Impact factor: 3.240

Review 5.  The clinical characteristics of dementia with Lewy bodies and a consideration of prodromal diagnosis.

Authors:  Paul C Donaghy; Ian G McKeith
Journal:  Alzheimers Res Ther       Date:  2014-07-21       Impact factor: 6.982

6.  18F-FDG PET for Prediction of Conversion to Alzheimer's Disease Dementia in People with Mild Cognitive Impairment: An Updated Systematic Review of Test Accuracy.

Authors:  Nadja Smailagic; Louise Lafortune; Sarah Kelly; Chris Hyde; Carol Brayne
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.